New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response. by Bartelink, IH et al.
UCSF
UC San Francisco Previously Published Works
Title
New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment 
Response.
Permalink
https://escholarship.org/uc/item/7vd5x940
Journal
Clinical and translational science, 10(5)
ISSN
1752-8054
Authors
Bartelink, IH
Zhang, N
Keizer, RJ
et al.
Publication Date
2017-09-01
DOI
10.1111/cts.12472
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Citation: Clin Transl Sci (2017) 10, 366–379; doi:10.1111/cts.12472
C© 2017 ASCPT. All rights reserved
ARTICLE
New Paradigm for Translational Modeling to Predict
Long-term Tuberculosis Treatment Response
IH Bartelink1,2, N Zhang1,3, RJ Keizer1,4, N Strydom1, PJ Converse3, KE Dooley3, EL Nuermberger3 and RM Savic1,∗
Disappointing results of recent tuberculosis chemotherapy trials suggest that knowledge gained from preclinical investigations
was not utilized to maximal effect. A mouse-to-human translational pharmacokinetics (PKs) – pharmacodynamics (PDs) model
built on a rich mouse database may improve clinical trial outcome predictions. The model includedMycobacterium tuberculosis
growth function in mice, adaptive immune response effect on bacterial growth, relationships among moxifloxacin, rifapentine,
and rifampin concentrations accelerating bacterial death, clinical PK data, species-specific protein binding, drug-drug inter-
actions, and patient-specific pathology. Simulations of recent trials testing 4-month regimens predicted 65% (95% confidence
interval [CI], 55–74) relapse-free patients vs. 80% observed in the REMox-TB trial, and 79% (95% CI, 72–87) vs. 82% observed
in the Rifaquin trial. Simulation of 6-month regimens predicted 97% (95% CI, 93–99) vs. 92% and 95% observed in 2RHZE/4RH
control arms, and 100% predicted and observed in the 35 mg/kg rifampin arm of PanACEA MAMS. These results suggest that
the model can inform regimen optimization and predict outcomes of ongoing trials.
Clin Transl Sci (2017) 10, 366–379; doi:10.1111/cts.12472; published online on 31 May 2017.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Disappointing results of recent TB chemotherapy tri-
als suggest that doses extrapolated from mice to humans
failed to accurately predict clinical efficacy and did not
account for at least three essential disparities: (1) limita-
tions in our ability to deliver “human-equivalent” PK profiles
to animals; (1) differences in immune system response and
disease-related pathology; and (2) much higher PK variabil-
ity in patients compared with genetically similar animals.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ Can systems pharmacology models address this
“translational gap”?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ Using preclinical exposure-response data, information
about disease pathology (i.e., cavitary vs. non-cavitary lung
disease), and immune responses linked with clinical PK,
the translational model developed here can inform regimen
optimization and predict outcomes of late-stage clinical
trials.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ Prospective testing of translational models is a critical
step toward bridging the preclinical-clinical divide in more
efficient and informative ways. It will eliminate some uncer-
tainty from drug development for TB and will be relevant
for other researchers working to bridge this divide across
disease areas.
Tuberculosis (TB) has surpassed human immunodeficiency
virus as the leading infectious cause of death worldwide.1
Current treatment for drug-susceptible TB—2 months of
rifampin (R), isoniazid (H), pyrazinamide (Z) and ethambutol
(E) followed by 4 months of RH (2RHZE/4RH), is considered
highly effective. However, this treatment is complex, lengthy,
consumes substantial health system resources, and results
in 5–10% of patients who relapse after treatment.1 Shorten-
ing drug regimens is a major objective of TB drug develop-
ment efforts.
Selection of regimens to test in clinical trials designed
to shorten treatment duration relies heavily on results from
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preclinical models. In an established mouse model of TB,
the substitution of rifapentine for rifampin at the same
10 mg/kg dose level significantly shortened the treatment
duration to achieve cure without relapse.2 The results
prompted a phase II trial (TBTC study 29) in which rifapen-
tine 10 mg/kg was substituted for rifampin in the first-line
regimen.3 The rifapentine dose was extrapolated directly
from mice to humans, without more sophisticated pharma-
cokinetic/pharmacodynamic (PK/PD) modeling and without
considering the impact of human PK variability or differences
in lung pathology. Unlike results in mice, the rifapentine-
containing regimen was not superior to control in study 29.3
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Because the murine studies demonstrated a clear
exposure-response relationship for both rifamycins,2,4–6
another clinical trial (TBTC study 29X) was performed in
which rifapentine doses ranged from 10 to 20 mg/kg.7 As
expected, patients with rifapentine plasma exposures in the
two higher tertiles had more rapid sputum culture conver-
sion and higher rate of change in Xpert MTB/RIF assays than
the lowest tertile.3,7,8 This result corroborated the hypoth-
esis that increasing rifapentine doses would increase effi-
cacy in humans, but again demonstrated that rifapentine
doses required to achieve superior efficacy over rifampin
were higher than anticipated based on results in mice.
Replacing isoniazid with moxifloxacin in the first-line regi-
men and in rifapentine-containing regimens accelerated bac-
terial killing and reduced the treatment duration necessary
for cure in mice by 1–2 months.9,10 Despite few assurances
that this effect in mice would translate to a 2-month treat-
ment reduction in humans,10 substitution of moxifloxacin for
isoniazid was examined in two phase III trials. Although it
did increase in the rate of sputum culture conversion, this
substitution was insufficient to successfully shorten treat-
ment from 6 to 4 months in the REMox-TB trial.11 Similarly,
replacing isoniazid withmoxifloxacin and rifampin with twice-
weekly rifapentine in the continuation phase was insufficient
to shorten treatment to 4 months in the Rifaquin trial.12
As PK/PD relationships between drug exposure and
antimicrobial effect at the site of infection are expected to
be largely invariant,13 they should be translatable from pre-
clinical models to the clinic. However, there are at least
three major challenges in translating efficacy between ani-
mals and patients: (i) difficulties replicating human PK pro-
files in animals; (ii) differences in disease-related pathology
and immune responses; and (iii) much higher PK variability in
patients.
Expecting that system’s pharmacology models can
address this “translational gap,” we hypothesized that a
model describing the interplay among bacterial growth, the
adaptive immune response, lung pathology, and the pharma-
cological relationships of drugs in the regimen would provide
better predictions of clinical efficacy. We compiled preclini-
cal PK/PD and clinical PK data and information on disease
pathology to build a translational mouse-to-human PK/PD
model. Then we used the model to predict PK/PD relation-
ships and long-term clinical trial outcomes, focusing on the
efficacy of rifampin, rifapentine, and moxifloxacin and their
contributions to regimens evaluated in recent phase III trials.
MATERIALS AND METHODS
Mouse studies
Published and unpublished PK/PD data from 2,187 BALB/c
and nude mice were used.2,9,14–16 Mice in each experi-
ment were block-randomized to treatment assignment after
aerosol infection with M. tuberculosis H37Rv. Depending on
the experiment and incubation period, the infectious dose
ranged from 2–5 log10 colony forming units (CFUs). Treatment
with one or more drugs began 3–61 days after infection. Mul-
tiple dose levels were administered: rifampin (R) from 2.5–640
mg/kg or rifapentine (P) from 5–20 mg/kg administered once
daily for 2, 5, or 7 days per week alone, or combined with
pyrazinamide (Z; 150–300 mg/kg daily) and either isoniazid
(H; 10–75 mg/kg daily) or moxifloxacin (M; 100 mg/kg daily
or twice daily) with or without ethambutol (E; 100mg/kg daily;
Table 1). Pyrazinamide was stopped after 8 weeks of treat-
ment in most experiments. Lung CFU counts were measured
at predefined intervals; up to 12 weeks after treatment initi-
ation for treated animals and up to 15 weeks for untreated
“control mice.”
Plasma samples for PK analysis were collected in sep-
arate studies after 3 weeks of administering rifampin and
rifapentine at daily doses ranging from 10–40 mg/kg and 5–
20 mg/kg, respectively, 5 days/week. Single-dose PK data
were available for moxifloxacin at doses ranging from 100–
400 mg/kg.
Data analysis
Analyses were performed using nonlinear mixed-effects
modeling (NONMEM VII software; ICON Development Solu-
tions, San Antonio, TX). Associated data analyses and visu-
alization were managed using R (R-3.1.1, Development Core
Team, 2013). The first-order conditional estimation with inter-
action method was used, whereas the model-building proce-
dure was guided by the likelihood ratio test, diagnostic plots,
and internal model validation techniques, including visual
predictive checks and bootstrap.
Pharmacokinetics of rifampin, rifapentine, and
moxifloxacin in mice
One-compartment and two-compartment models with linear
and nonlinear absorption and elimination were tested. First,
population PK parameters (θ ) for clearance (CL), bioavailabil-
ity, and rate of absorption (Ka) per dose level were estimated
from the data. Models incorporating absorption lag times and
zero-order and first-order absorption and elimination were
also evaluated. Interindividual variability values for CL, Vd, or
bioavailability were assumed to be log-normally distributed.
Residual variability was described using a proportional error
model.
Model describing bacterial growth dynamics, with
or without treatment, in immune-competent
and immune-deficient mice
A baseline model was established to describe the growth of
bacteria without drug treatment or the effect of the immune
system. The residual error was split into two components:
one to account for errors with each experiment and one to
account for study-arm-specific difference replication resid-
ual error (RRES) to avoid bias due to correlations.29 Interindi-
vidual variability was estimated on baseline CFU counts and
maximum CFU counts (Bmax). As the distribution of the base-
line was not normal, heavy tail, box cox, and binomial distri-
butions of the baseline ε were estimated.
The baseline model was followed by the addition of
rifapentine, rifampin, and moxifloxacin treatment response
data. First, the antimicrobial effect of the drug (Edrug) was esti-
mated as an effect per dose level to determine the shape of
the correlation. The model of drug dose-effect was evaluated
individually using a proportional effect on bacterial death or
bacterial growth. Then, the drug concentration-effect rela-
tionship was modeled using linear or nonlinear (Emax) equa-
tions. In addition, the presence of a time delay between
www.cts-journal.com
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Table 1 Characteristics of tuberculosis treatment studies conducted in mice
Doses, mg/kgaImmune
function
No. of
samples
Concomitant
drugs R P M Z H E
Frequency,
weekly-1 Cssb
PK (Conc. time
profiles)
Moxifloxacin Yes 72 No – 150 (100–400) – – – Single
dose
No
Rifapentine Yes 69 No 10 (5–20) – – – – 5/7 Yes
Rifampin Yes 66 No 15 (10–40) – – – – 5/7 Yes
PD (CFU data)c
No treatment Yes 477 No – – – – – – – Yes
No 50 No – – – – – – –
Rifapentine Yes 32 P – 5 (5–10) – 0 0 – 5/7
Yes 67 PZH – 15 (10–20) – 150 (150–300) 75 (10–75) –
No 10 PZH – 10 – 150 10 – 5/7
Yes 8 PZHE – 10 – 150 10 100 5/7
Rifampin Yes 168 R 10 (2.5–640) – – 0 0 – 5/7
Yes 578 RZH 10 (10–15) – – 150 (150–300) 12.5 (0–75) – 2/7, 5/7,
7/7
No 35 RZH 10 – – 150 10 – 2/7, 5/7,
7/7
Yes 172 RHZE 10 – – 150 (0–150) 10 (10–25) 100 5/7, 7/7
No 258 RHZE 10 (3–30) – – 150 (0–150) 10 (0–30) 100 5/7, 7/7
Moxifloxacin Yes 71 PMZ 15 (7.5–20) 200 (100–200) 150 (150–300) 0 – 5/7, 7/7
Yes 207 RMZ 10 (10–15) 200 (100–200) 150 (150–300) 0 (0–75) – 5/7, 7/7
Yes 54 RMZE 10 100 150 0 100 5/7
CFU, colony forming unit; Conc., concentration; Css, steady-state concentration; E, ethambutol; H, = isoniazid; M, moxifloxacin; P, rifapentine; PD, pharmaco-
dynamic; PK, pharmacokinetic; R, rifampin; Z, pyrazinamide.
Immune function yes = BALB/c mice, immune function no = nude mice.
The medians (ranges) of values are presented, unless specified otherwise.
aDrugs for the PD studies were administered at multiple dose levels: rifampin (R) from 2.5 to 640 mg/kg or rifapentine (P) from 5 to 20 mg/kg administered once
daily for 2, 5, or 7 days per week alone, or combined with pyrazinamide (Z; 150–300 mg/kg daily) and either isoniazid (H; 10–75 mg/kg daily) or moxifloxacin (M;
100 mg/kg daily or twice per day) with or without ethambutol (E; 100 mg/kg daily). bSteady-state plasma samples for PK analysis were collected after 3 weeks
of dosing rifampin and rifapentine at daily doses ranging from 10–40 mg/kg and 5–20 mg/kg, respectively, 5 days per week; single-dose PK data were available
for moxifloxacin at doses ranging from 100–400 mg/kg. cLung CFUs were measured in the homogenized lungs of mice euthanized at predefined intervals, up
to 12 weeks following treatment initiation for treated animals and up to 15 weeks for untreated “control mice.” In some studies, the proportion of mice with
culture-positive relapse 12 weeks after completing various durations of treatment was assessed.
drug administration and the observed effect was explored by
introducing an effect compartment (Ce), with the effect delay
characterized by a first-order rate constant (ke).
Clinical trial simulations using a translational
pharmacokinetic/pharmacodynamic model
PK/PD relationships in patients were simulated by integrat-
ing patient PK parameters, species-specific protein binding,
drug-drug interactions, and patient-specific disease pathol-
ogy (e.g., lung cavities and immunodeficiency), together
with treatment response information and immune responses
derived from mice (Figure 1 and Table 2).5–7,17–28
Patient-derived PK parameters of moxifloxacin,17,18
rifampin,30 and rifapentine5 were derived from the literature
(Table 2) and dose-dependent bioavailability and/or clear-
ance of rifamycins was considered.7,19,20 Effects of drug-drug
interactions of rifamycins on moxifloxacin clearance were
included21,31 as was the effect of food on rifapentine.20
As free fractions of drugs in plasma were presumed to be
the active fractions, the effective concentration in patients
was adjusted using ratios of literature-derived free fractions
between humans and mice (Table 2).22–25 Baseline CFU
counts observed in the HIGHRIF1 trial were implemented.26
The adaptive immune response of patients without immun-
odeficiency was considered similar to the immune function
during chronic infection derived from mice at day 60 postin-
fection in combination with drugs (Kimmune = 1.22 × 10−3
day−1). The immune response was predicted to be steady
throughout treatment, consistent with other studies of
immune response in TB.32
Effects of disease pathology on PK/PD were explored
(Table 2). Reduction in the adaptive immune effect was
implemented to estimate drug efficacy in patients with
immunodeficiency (e.g., advanced human immunodeficiency
virus infection) by simulating with immune parameters
between 0 and the estimated effect. The effects of 10%
retention of rifampin at the site of action compared with
plasma27 and fourfold higher EC50 of rifapentine were
explored.28
Regimens and dosing schedules of clinical trials were
introduced to generate plasma concentration-time profiles
at steady state and CFU counts during treatment and for
1 year post-treatment. These were simulated in 200 hypo-
thetical subjects per study arm.
Clinical and Translational Science
Translational Modeling Predicts TB Treatment Response
Bartelink et al.
369
Figure 1 A translational pharmacokinetic/pharmacodynamic (PK/PD) model derived from mouse data used to predict colony forming
unit (CFU) counts in patients. In this translational model, we assumed the following characteristics: (i) that the rate of bacterial growth
in BALB/c mice and in human patients with drug-sensitive pulmonary tuberculosis (TB) are the same, and (ii) that the concentration-
response relationship in mice and human patients at the site of action is the same. Therefore, the parameters assumed to be equivalent
to the preclinical values are not highlighted, whereas the patient-based parameters are highlighted in red. Baseline, number of bacteria
at inoculation; Bmax, maximum number of bacteria; γ , the sigmoidicity factor, which defines the shape of the relationship; γ immune response,
the sigmoidicity factor, which defines the shape of the immune system – bacterial effect relationship; IT50, the time that produces 50%
of the maximum immune effect; Kdeath, bacterial death constant; Kgrowth, bacterial growth constant; M, moxifloxacin; P, rifapentine; R,
rifampin; θKDOI.0, immune killing rate in treated animals at average incubation time; θKDOI.t, the increase in killing rate in experiments with
a longer than average incubation period; θKIND, the maximum immune dependent killing rate in untreated animals; EC50, the antibiotic
concentration that produces 50% of the maximum effect; Edrug, effect with a certain drug treatment; Emax, the maximal achievable effect
with a certain drug treatment.
Numbers of relapse-free and culture-negative subjects
were estimated as the numbers of patients with CFU <1 at
the relevant time points. Long-term treatment response was
defined as the number of patients with CFU <1 at 1 year
(using a cure boundary).33
RESULTS
Pharmacokinetics of rifampin, rifapentine,
and moxifloxacin in mice and human patients
The model building process of PK in mice and results are
described in detail in Supplementary Table S2 and final
model results are shown in Figure 2a, Supplementary Table
S1a, and Supplementary Figure S1. For none of the three
drugswere area under the curve (AUC) and peak plasma con-
centration (Cmax) comparable to those in patients receiving
the same mg/kg dose at steady-state concentration (Sup-
plementary Figure S2). In addition, these exposure param-
eters could not be predicted using conventional allometric
scaling of CL and Vd, demonstrating that we should not rely
on mouse dosing or allometric scaling34,35 of preclinical PK
parameters alone to predict clinical PK or equivalent doses.
Model describing bacterial growth dynamics,
with or without treatment, in immune-competent
and immune-deficient mice
The Gompertz model (Eq. (1)) was used to describe the
number of viable bacteria as a function of net growth rate
(Knet) and the maximum growth rate when the mouse lung
is saturated (Bmax)36 (Figure 3a). As incubation times varied
between experiments, a binomial distribution of ε (variabil-
ity on baseline estimation) improved the model ( objective
function value [OFV] = −8.6; df +1; P < 0.01). Knet did not
significantly differ among experiments with either a long or
short incubation period (0.68 relative standard error [RSE]
5% vs. 0.64 RSE 6%, respectively). In addition, Knet was sim-
ilar in BALB/c mice and nude mice (0.63 day−1 RSE 6% vs.
0.69 day−1 RSE 26%, respectively). However, CFU count-
time profiles of immune-competent mice showed that Knet
gradually reduced due to the onset of the adaptive immune
response (Kimmune).
dB
dt
= Knet ×
(
1 − B
Bmax
)
× B − (Kimmune ) × B (1)
www.cts-journal.com
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Table 2 Parameters used for translational pharmacokinetic/pharmacodynamic model of rifampin, rifapentine, and moxifloxacin to predict colony forming unit
counts in patients
Parameters Parameter Rifampin Rifapentine Moxifloxacin
Protein
binding
Ratioa 0.11 patients25/0.04 mice6 0.02 patients23/0.04 mice24 0.55 patients22/0.69 mice22
PK model
patients
Model 1-Compartment linear model 2-Compartment linear model, with
induction of CL over time and dose
dependent bioavailability
2-Compartment linear model
PK parame-
ters
CL: 602.4 L/day18
V1: 69.5 L
KA: 27.6/day
LAG: 0.1 day
CL: 44.6 L/day*1.2 (induction)7 CL: 254.4 L/day17
V1: 114 L
V2: 89.8 L
KA: 6 day-1
Dose-dependent clearance:
CL (600 mg R): 602.4 L/day19
CL (900 mg R): 446.4 L/day19
V2: 51.7 mg/L5
V2 (600 mg): 53.2 mg/L
V2 (900 mg and 1,200 mg): 53.2 mg/L
Q: 51.36 L/day
F1: 1
CL (1,200 mg R): 391.2 L/day19 KA: 40.56 d−1 5
KA (600 mg R): 27.6 d−1
KA (900 mg R): 27.6 d−1
KA (1,200 mg R): 27.6 d−1
F1 (fraction):7,20
600-mg dose 0.91
900-mg dose 0.83
1,200-mg dose 0.74
Drug-drug
interaction
P on M: CL*1.0821
R on M: CL*1.3031
Food effect NA F (fraction) at 1,200 mg dose:20
Fasting fraction 0.76
Low-fat food fraction 0.82
High-fat fraction 0.86
Egg fraction 0.82
NA
PK/PD
model TB
patients
Baseline
model
dB
dt =Knet × B−(Kimmune + Edrug) × B
Baseline CFU count: 6 log10 CFU/mL26
Knet: 0.65 (derived from mouse model)
Kimmune: 1.22 × 10−3 d−1(maximum immune effect derived from mouse model)
Drug effect Edrug = E0 + (
(E0+Emax )×C
γ
adj
ECγ50+C
γ
adj
)
Derived from mouse model:
EC50: 1.77 mg/L
γ : 0.23
Emax; 1.64 d−1
additional effect EHZ:0.0172 d−1
additional effect EHZE:0.0243 d−1
additional effect EMZ: 0.161 d−1
Edrug = E0 + (
(E0+Emax )×C
γ
adj
ECγ50+C
γ
adj
)
Derived from mouse model:
EC50: 0.50 mg/L
γ : 0.86
Emax; 1.00 d−1
additional effect EHZ: -0.0156 d−1
additional effect EMZ: 0.07 d−1
Edrug = E0 + (E × Cadj )
Derived from mouse model:
E: 3.279 g/L
additional effect EE: 0.0344
d−1
Disease
pathology
PK/PD at the
site of
action
Prolonged retention time at site of action: Effect compartment with 10% longer retention compared with plasma27
Rifapentine EC50 fourfold higher in cavity compared with noncavity28
Immunity Reduced levels of immunity by changing the immune parameters between 0 and the estimated effect
Kimmune = 0− max 1.22 × 10−3d−1
Dosing
schedules
REMox-TB
trial
Control arm: (Months 0–2) Rifampin 10 mg/kg, isoniazid 300 mg, pyrazinamide 25 mg/kg, and ethambutol 20 mg/kg,
daily; (Months 2–6) Rifampin 10 mg/kg and isoniazid 300 mg daily.
Ethambutol arm: (Months 0–2) Rifampin 10 mg/kg, moxifloxacin 400 mg, pyrazinamide 25 mg/kg, and ethambutol
20 mg/kg daily; (Months 2–4) Rifampin 10 mg/kg and moxifloxacin 400 mg daily
Rifaquin trial Control arm: (Months 0–2) Rifampin 10 mg/kg, isoniazid 300 mg, pyrazinamide 25 mg/kg, and ethambutol 20 mg/kg
daily; (Months 2–6) Rifampin 10 mg/kg and isoniazid 300 mg daily.
Four-month arm: (Months 0–2) Rifampin 10 mg/kg, moxifloxacin 400 mg, pyrazinamide 25 mg/kg, and ethambutol
20 mg/kg daily; (Months 2–4) Rifapentine 15 mg/kg and moxifloxacin 400 mg twice weekly.
Six-month arm: (Months 0–2) Rifampin 10 mg/kg, moxifloxacin 400 mg, pyrazinamide 25 mg/kg, and ethambutol
20 mg/kg daily; (Months 2–6) Rifapentine 20 mg/kg and moxifloxacin 400 mg weekly.
(Continued)
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Table 2 Continued
Parameters Parameter Rifampin Rifapentine Moxifloxacin
TBTC study
31
Control arm: (Months 0–2) Rifampin 10 mg/kg, isoniazid 300 mg, pyrazinamide 25 mg/kg, and ethambutol 20 mg/kg
daily; (Months 2–6) Rifampin 10 mg/kg and isoniazid 300 mg daily.
Four-month arm: Rifapentine arm: (Months 0–2) Rifapentine 1,200 mg, isoniazid 300 mg, pyrazinamide 25 mg/kg, and
ethambutol 20 mg/kg daily; (Months 2–4) Rifapentine 1,200 mg and isoniazid 300 mg daily.
Rifapentine and moxifloxacin arm: (Months 0–2) Rifapentine 1,200 mg, isoniazid 300 mg, moxifloxacin 400 mg, and
pyrazinamide 25 mg/kg daily; (Months 2–4) Rifapentine 1,200 mg, isoniazid 300 mg, and moxifloxacin 400 mg daily.
CFU, colony forming unit; CL, clearance; F1, bioavailability; KA, absorption constant; LAG, lag-time; M, moxifloxacin; NA, not applicable; P, rifapentine; PD,
pharmacodynamic; PK, pharmacokinetic; Q, the intercompartmental rate; TB, tuberculosis; V1, volume of distribution of the central compartment; V2, volume of
distribution of the second compartment.
Baseline, number of bacteria at inoculation; Bmax, maximum number of bacteria; Edrug, effect with a certain drug treatment; Emax, the maximal achievable effect
with a certain drug treatment; EC50, the antibiotic concentration that produces 50% of the maximum effect; Knet, bacterial net growth constant; Kimmune, estimated
immune killing rate (at maximum effect as observed in mice); γ , the sigmoidicity factor that defines the shape of the relationship; Cadj, adjusted concentration:
the free fraction of drug in plasma was presumed to be the active fraction, therefore, the effective concentration in patients was adjusted using the ratio in free
fraction between humans and mice was derived from the literature.
aRatio of free fraction in humans/free fraction in mice.
The parameters assumed to be equivalent to the preclinical values derived in mice are not highlighted, whereas the patient-based and literature derived parameters
are highlighted in red.
B= bacterial count in mouse lungs (log CFU); Bmax = max-
imal bacterial count that can be reached in mouse lungs;
Kg = bacterial growth rate; and Kd = natural bacterial death
rate.
In Eq. (1), the onset of the adaptive immune-dependent
killing effect (Kimmune) was first introduced using a lag-time
(OFV −43.5; df +2; P < 0.01). A sigmoid-shaped function
with γ as the sigmoidicity factor and an onset (IT50) 4 weeks
after incubation improved the model (OFV = −75; df −2;
P < 0.001; Eq. (2) left). This time-varying function optimally
described the immune system-time-bacterial effect relation-
ship (Figure 3b).
Kimmune =
(
θKIND × timeγ
IT γ50 + timeγ
)
+
(
θKDOI.0 + incubation timemean × θKDOI.t
)
(2)
Based on data from treated and untreated BALB/c mice,
Kimmune was further separated into immune-dependent killing
in the absence (Eq. (2) left; Figure 3b) or presence (Eq. (2)
right; Figure 3c) of drugs. In treated animals, the effect of the
immune function showed a linear correlation with time after
inoculation using θKDOI in Eq. (1) (in the presence of drugs,
θKIND = 0). This linear model showed an improved fit com-
pared with a categorical model of chronic and acute infec-
tion (OFV = −20; df −1; P < 0.01) with a minimum incu-
bation period of 3 days. The estimated immune-dependent
killing effect resulted in distinctly different profiles in acute
and chronic mouse infection models (Figure 3c).
The observed and predicted data of immune-dependent
killing and drug-dependent killing are shown in Figure 2b and
model parameters are presented in Supplementary Table
S1b.
Drug effect model in mice
In the full PK/PD model, the bacterial growth dynamics sub-
model and the mouse population PK model were combined,
and equations were introduced that characterized the effect
that the drug imposed on the bacteria (Supplementary Table
S1).
Models with individual drug effects (Edrug) enhancing the
bacterial death rate (Eq. (3) using an additive, or Eq. (4) a pro-
portional model) or inhibiting the bacterial growth rate (Eq. (5))
were first evaluated by dose level and concentration level.
In these subanalyses, Knet was separated into a bacterial
growth rate (Kg) and a natural bacterial death rate (Kd, Eq.
(3)–(5)).36 A Kg of 0.78/day was adapted from Gill et al.37 (day
0–13 experiment).
dB
dt
= Kg ×
(
1 − B
Bmax
)
×B− (Kd + KIND + KDOI + Edrug) × B (3)
dB
dt
= Kg ×
(
1 − B
Bmax
)
×B− ([Kd + KIND + KDOI] × [1 + Edrug]) × B (4)
dB
dt
= Kg ×
(
1 − Edrug
) ×
(
1 − B
Bmax
)
×B− (Kd + KIND + KDOI ) × B (5)
Rifampin
Dose-mediated bacterial killing by rifampin was best
described with a function of drug effect enhancing bacte-
rial death rate (Eqs. (3) and (4); Supplementary Figure 4a)
compared with inhibiting bacterial growth (Eq. (5); OFV =
−937; df 0; P< 0.01). Proportional and additive models (Eqs.
(3) and (4)) provided the same results. The bacterial-killing
effect of rifampin was nonlinearly dependent on drug dose
and concentration level (Supplementary Figure S4a). A non-
linear Emax model significantly improved the model fit com-
pared with a linear model (OFV = −718; df +1; P < 0.01;
Supplementary Figure S4a). A sigmoidal Emax function (Eq.
(7)) with an EC50 of 1.79 mg/L (RSE = 20%) best described
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Figure 2 (a) Observed and model-predicted concentrations of
moxifloxacin, rifapentine and rifampin per dose level (in mg/kg).
Solid lines are population predicted values, dotted lines are
individual predicted values (no inter-individual variability could
be estimated in the moxifloxacin model) and dots are the
observed data. (b) Observed and model-predicted colony form-
ing unit (CFU) counts of several components of the pharmacoki-
netic/pharmacodynamic (PK/PD) data and model: CFU counts in
untreated immune competent (black) and immune deficient (green)
mice and the effect of treatment with rifampin 10 mg/kg, isoni-
azid 10 mg/kg, and pyrazinamide 150 mg/kg in immune compe-
tent (blue) and immune deficient (red) mice. Solid lines are popu-
lation predicted values, dotted gray lines are individual predicted
trial results (in which variability in baseline and Bmax was included
and dots are the observed data.
the concentration-effect relationship in mice (Supplemen-
tary Figure S4a,b,e, Supplementary Table S1c). Inclusion
of delayed effect did not significantly improve the model
(OFV −1.4; df −1; P = 0.237). This model was able to pre-
dict CFU change at dosing frequencies of 1, 2, and 5 days
per week (Supplementary Figure S4e).
Edrug = E × C (6)
Edrug =
(
Emax × Cγ
ECγ50 + Cγ
)
(7)
Emax indicates the maximal achievable antibacterial effect
with a certain drug; EC50 is antibiotic concentration produc-
ing 50% of Emax; and γ is the sigmoidicity factor.
Rifapentine
A function to describe the dose-response enhancing the bac-
terial death rate was also the best fit for rifapentine (Eq. (3)) as
compared with a model with drug effect inhibiting bacterial
growth (Eq. (5); OFV = −686; df 0; P = 0.001; Supplemen-
tary Figure S4c). The concentration-effect relationship was
best described using a sigmoidal Emax model (Eq. (7)) with an
EC50 of 0.5 mg/L (RSE = 46%; Figure 3e; Supplementary
Figure S4c,d, and Supplementary Table S1c).
Comparison of rifamycin concentration-effect relation-
ships in mice shows that at the same concentration,
rifampin Emax is significantly higher and IC90 lower compared
with rifapentine (Supplementary Table S1; Supplementary
Figure S5a). However, in these once-daily dosing studies,
the EC90 of rifapentine was reached for a prolonged time
period compared with rifampin at the same dose level. In
mice receiving 10 mg/kg 5 days/week, rifapentine reached
the EC90 of 0.9 day−1 75% of the time, vs. 25% for rifampin
(Supplementary Figure S5b).
Moxifloxacin
The drug-mediated-killing effect of moxifloxacin was tested
in combination with isoniazid and pyrazinamide. The PK/PD
model for moxifloxacin could be described with a drug effect
either inhibiting the bacterial growth rate or enhancing the
bacterial death rate (OFV = +1; df +0; NS). In the dose
range of 0–200 mg/kg, the data were best described using
a linear correlation (Eq. (6)) between moxifloxacin concentra-
tion and drug effect (Figure 3g; Supplementary Figure S4f).
The EC50 of moxifloxacin in mice was not reached with a 200
mg/kg dose, corresponding to an AUC between 40 and 45
mg*h/L, equivalent to that observed in patients receiving 400
mg (Supplementary Figure S2 and Supplementary Table
S1c).
Composite drug effect of combination treatment
The effect of other components in the drug regimen (i.e.,
150 mg/kg pyrazinamide, 25 mg/kg isoniazid, and/or 100
mg/kg ethambutol) was described using an extra efficacy
term: (E0) on Kd (Eq. (8)) to capture antagonistic, additive, or
synergistic effects of the additional drugs.
Edrug = E0 +
(
(E0 + Emax) × Cγ
ECγ50 + Cγ
)
or
Edrug = E0 + (E × Cmoxifioxacin ) (8)
Only a small beneficial effect of adding once daily dosing
of 150 mg/kg pyrazinamide and 25 mg/kg isoniazid, with or
without 100 mg/kg ethambutol, to rifampin was estimated;
HZ to rifampin (EHZ) was 0.017 d−1 (RSE 59%) and E on top
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of RHZ (EHZE) was 0.024 d−1 (RSE 97%; Figure 3f; Supple-
mentary Table S1c, and Supplementary Figure S4b).
A small but significant decrease in drug effect was esti-
mated when adding daily pyrazinamide and isoniazid to
rifapentine (EPHZ by −0.015; RSE 50; Figure 3f, and Sup-
plementary Table S1c).
The effect of a regimen includingmoxifloxacin at both dose
levels in combination with rifampin 10mg/kg or rifapentine 10
mg/kg, pyrazinamide and ethambutol (but not isoniazid) were
larger compared with the control group with isoniazid instead
of moxifloxacin (Supplementary Figure S4g). Simulations of
moxifloxacin 200 mg/kg alone using the estimates of its con-
tribution to the combination with rifampin and pyrazinamide
predicted only limited bacteriostatic activity, whereas, in prior
studies, a bactericidal effect of moxifloxacin monotherapy-
was observed in mice38,39 (Figure 3g, gray line). The effi-
cacy of moxifloxacin was larger when it was combined with
rifampin at 10 mg/kg (0.161 d−1; RSE 3%; compared with
rifapentine at 10 mg/kg; 0.07 d−1; RSE 50%; Supplemen-
tary Table S1c and Supplementary Figure S4g). Also, only
a small beneficial effect of adding ethambutol (0.0344 d−1;
RSE: 30%) to the RMZ combination was estimated (Supple-
mentary Table S1c).
Clinical trial simulations using a translational
pharmacokinetic/pharmacodynamic model
A visual presentation of the translational PK/PD model is
shown in Figure 1 and parameters are shown in Table 2.
Can the translational model predict
pharmacokinetic/pharmacodynamic relationships
in patients?
We tested dose increases of rifampin and rifapentine and
compared results to observations in the TBTC study 29X,7
HIGHRIF2,19 and PanACEA MAMS trials.40 Rifapentine dose
escalation from 10 to 40 mg/kg had a beneficial effect on
regimen efficacy (Supplementary Figure S6a), and the pre-
dicted responses were in agreement with the observed data
of TBTC study 29X,7 (Table 3 and Supplementary Figure
S7a). Proportions of participants predicted to have neg-
ative cultures at 8 weeks were comparable to observed
data in all rifapentine arms: for 10 mg/kg, 88.6% pre-
dicted (95% confidence interval [CI], 82–94%) vs. 87.1%
observed; for 15 mg/kg, 97% predicted (95% CI, 93–100%)
vs. 96.7% observed; for 20mg/kg, 98.8%predicted (95%CI,
95–100%) vs. 89.7% observed, respectively (Supplemen-
tary Figure S7c, Table 3). None of the patients was pre-
dicted to relapse at 1 year after completing 4–6 months of
treatment.
To account for possible overprediction by the model,
we explored revising the expected PK/PD relationship
for rifapentine in the presence of cavitary TB. Rifapen-
tine penetration into cavitary lesions may be reduced.28
In TBTC studies 29 and 29X, one-third of the subjects
had cavitary lesions.28 In those with cavities 4 cm, a
higher exposure did not reduce the estimated average time
to stable culture conversion, whereas in others without
large cavities, a clear exposure-response relationship was
observed.28 Supplementary Figure S6e shows simulation
results of a weaker rifapentine-mediated killing effect in
cavities.
Consistent with results from recent clinical trials,18,19,40 our
simulations showed that high-dose rifampin (35–40 mg/kg)
improved treatment outcomes (Supplementary Figure S6b).
The proportion of participants predicted to be culture-
negative at 8 weeks for rifampin at 10 mg/kg was 38.5%
(95%CI, 30–47) vs. 77%observed; at 15mg/kg, 60.9% (95%
CI, 50.5–70) vs. 74% observed; and at 20 mg/kg, 72.2%
(95% CI, 63.5–80) vs. 80% observed, showing underpredic-
tion of rifampin’s killing effect at 10 mg/kg, but more accu-
rate prediction for higher doses (Supplementary Figure S7b,
Table 3). One year after completing 6 months of treatment
(assuming 4 months of HR10mg/kg in the continuation phase),
3% of patients were predicted to relapse in the control arm
vs. 3% observed, and in the 35mg/kg rifampin group none of
the patients was predicted to relapse, which is in agreement
with the PanACEA MAMS trial results40 (Supplementary
Figure S7d, Table 3).
Rifampin shows prolonged retention and accumulation in
caseous lung lesions.27 The relatively rapid clearance from
plasma may enhance this effect in comparison with other
drugs.27 Therefore, we explored whether a prolonged reten-
tion time at the site of action might account for the under-
prediction of the rifampin 10 mg/kg effect at 8 weeks.27
Supplementary Figure S6c shows that, at 10% retention
in the lung, the drug-mediated decline in CFU counts is
steeper. Thus, including disease pathology in the model pro-
duced better predictions of PK/PD relationships for both
rifamycins. The model confirmed the observed efficacy of
rifampin-containing regimens, including improved outcomes
with higher doses.18 The model also confirmed the clinical
observation that increasing the rifapentine dose had only
a small beneficial effect on the responses in subjects with
cavities 4 cm.28 The results suggest that the influence of
caseous lesions on rifamycin distribution and retention is one
reason that PK/PD relationships based on plasma exposures
in BALB/c mice may not translate directly to human patients
with cavitary TB.
Can the translational model predict long-term efficacy?
We tested substituting moxifloxacin for isoniazid and com-
pared the results to observations from the REMox-TB11
and Rifaquin12 trials. This substitution did not improve
predicted outcomes for patients receiving rifampin (Sup-
plementary Figure S8a), but did improve predicted out-
comes for those receiving rifapentine (Supplementary
Figure S8b).
Simulations of the REMox-TB11 and the Rifaquin12 trials
are shown in Figure 4a. They did not predict themodest ben-
eficial effect of substituting moxifloxacin for isoniazid on spu-
tum culture conversion at 8 weeks observed in the REMox-
TB and Rifaquin trials (Supplementary Figure S8, Table 3).
However, as observed in both trials, the simulations pre-
dicted that the substitution was insufficient to shorten the
treatment duration to 4 months (Figure 4a). In the REMox-
TB trial, the number of relapse-free patients in the 4-month
2RMZE/2RM arm was 65% (95% CI, 55–74) predicted vs.
80% observed; and in the control arm 97% (95% CI, 93–99)
predicted vs. 92% observed (Figure 4b, Table 3). In the
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Figure 3 Components of the pharmacokinetic/pharmacodynamic (PK/PD) model. (a) Baseline model of bacterial growth in mice without
immune function (red). (b) Bacterial growth in untreated mice is dependent on the immune competency (immune-competent BALB/c mice,
blue; immune-deficient nude mice, red). (c) The additive effect of immune function on the killing effect of rifampin (R) alone is smaller in
acute infection models (5-day [green] or 14-day [blue] incubation period prior to treatment onset [time 0]) compared with a chronic infection
model (61-day incubation period (red). Simulation of the concentration-colony forming unit (CFU) count relationship of (d) rifampin alone,
or (e) rifapentine (P) alone, at different dose levels tested in the mouse model. (f) The effect of combining R or P with isoniazid (H) 25 mg/kg
and pyrazinamide (Z) 150 mg/kg ± E 100 mg/kg in immune-competent mice. (g) The estimated effect of moxifloxacin in combination with
R10 mg/kg and Z 150 mg/kg and predicted effect of moxifloxacin alone*. E, ethambutol; M, moxifloxacin. *Moxifloxacin alone simulations
alone effect was based on the difference in effect between rifampin/ pyrazinamide and rifampin/moxifloxacin/pyrazinamide.
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Table 3 Predictions of efficacy in clinical trials using the translational pharmacokinetic/pharmacodynamic model and comparison to the observed trial outcomes
Predicted data 8 weeks 1 year
Observed data 8
weeks Negative
End of
treatment
Study Arm
CFU
(mean, 95% CI)
TB free
(%, 95% CI)
TB free
(%, 95% CI)
culture at 8
weeksa
Favorable
outcomeb
Study 29x
Control 2R10HZE/4RH 2.98 0.00 9.29 39 30 47 97 93 99 52/64 (81.3%)
P10 2P10HZE/4RH 0.47 0.00 3.49 89 82 94 100 100 100 54/62 (87.1%)
P15 2P15HZE/4RH 0.12 0.00 1.63 97 93 100 100 100 100 58/60 (96.7%)
P20 2P20HZE/4RH 0.11 0.00 1.51 98 95 100 100 100 100 26/29 (89.7%)
HIGHRIF2/ PanACEA MAMS
2R10HZE/4RH 2.98 0.00 9.29 39 30 47 97 93 99 11/48 (77%) 3/105 (95%)
2R15HZE/4RH 1.72 0.00 7.58 61 50 70 99 97 100 12/48 (74%)
2R20HZE/4RH 1.19 0.00 6.59 72 63 80 100 98 100 9/47 (80%)
PanACEA MAMS
2R35HZE/4RH 0.35 0.00 3.94 92 86 97 100 100 100 0/52 (100%)
2R20MHZ/4RH 0.80 0.00 4.58 82 75 90 100 99 100 0/58 (100%)
REMox-TB
Control 2RHZE/4RH 2.98 0.00 9.29 39 30 47 97 93 99 393/474 (83%) 510/467 (92%)
Ethambutol-arm 2RMZE/2RM 4.43 0.00 11.68 26 18 34 65 55 74 448/517 (87%) 524/419 (80%)
Rifaquin trial
Control 2RHZE/4RH 2.98 0.00 9.29 39 30 47 97 93 99 187/219 (85.3%) 155/163 (95%)
Four-months 2RMZE/2PM2week 4.43 0.00 11.68 26 19 36 79 72 87 394/436 (90.4%) 135/165 (81.8%)
Six-months 2RMZE/4PM1week 4.43 0.00 11.68 26 19 36 81 73 91 174/186 (93.5%)
Study 31
Control 2RHZE/4RH 2.98 0.00 9.29 39 30 47 97 93 99 study ongoing
2P1200HZE/2P1200H 0.02 0.00 0.29 99 95 100 100 100 100
2P1200HZM/2P1200HM 0.02 0.00 0.24 99 95 100 100 100 100
R to P, high-dose M
4RMZE 2.08 0.00 5.57 25 18 34 64 50 63
4RM800ZE 1.82 0.00 5.04 27 19 36 68 56 77
4PMZE 0.00 0.00 0.00 100 100 100 100 100 100
4PM800ZE 0.00 0.00 0.00 100 100 100 100 100 100
R to P, high-dose M
Control 2RHZE/4RH 2.98 0.00 9.29 39 30 47 97 93 99
2R35HZE/2RH 0.35 0.00 3.94 92 86 97 100 100 100
CFU, colony forming unit; CI, confidence interval; E, ethambutol; H, isoniazid; M, moxifloxacin; P, rifapentine; R, rifampin; TB, tuberculosis; Z, pyrazinamide.
aIntention to treat + solid culture data. bFavorable outcome at the end of treatment at 1 year or at the last study time point.
Rifaquin trial, the number of relapse-free patients in the
4-month arm was 79% (95% CI, 72–87) predicted vs. 81.8%
observed; and in the control arm 97% (95% CI, 93–99)
predicted vs. 95% observed (Table 3, Figure 4b). These
results show that the model accurately predicted the most
relevant clinical outcome—cure without relapse (Figure 4b,
Table 3).
Can the translational model predict the results of
ongoing trials?
To prospectively explore outcomes of ongoing trials, we
tested substituting high-dose rifapentine for rifampin with or
without also substituting moxifloxacin for ethambutol to mir-
ror TBTC study 31 (NCT02410772) in which two 4-month
arms (2P1200mg HZE/2P1200mg H and 2P1200mg HZM/2P1200mg
HM) are compared with 2RHZE/4RH. After 4 weeks of treat-
ment, the predicted lung log10 CFU count in the 2P1200mg
HZE/2P1200mg H group was 2.06 (0.70–3.22) and in the
2P1200mg HZM/2P1200mg HM group was 2.07 (0.77–3.24) vs.
7.63 (3.89–11.43) in the control arm (Figure 4c). At 4 months
and beyond, all simulated patients in the two 4-month study
arms had negative cultures and their disease did not relapse
(Figure 4c, Table 3).
The effect of immune status was tested in simulations
of TBTC study 31 by reducing the immune function to
lower values between 0 and the estimated effect (Kimmune 0-
1.22 × 10−3 day−1 d−1). Immunodeficient patients receiving
2P1200mg HZE/2P1200mg H or 2P1200mg HZM/2P1200mg HM
showed good responses, whereas 2RHZE/4HR was not pre-
dicted to have a durable response (Supplementary Figure
S7d).
We also tested whether high-dose rifampin (2R35mg/kg
HZE/2R35mg/kg H) could shorten treatment to 4 months. None
of the patients was predicted to have their disease relapse at
1 year (Figure 4d, Table 3).
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Figure 4 Pharmacokinetic/pharmacodynamic (PK/PD) simulations of patient outcomes in trial scenarios. (a) Simulated sputum colony
forming unit (CFU) counts and drug concentrations in patients receiving treatment with the control regimen or moxifloxacin 400 mg in
combination with pyrazinamide, ethambutol, and either rifampin or rifapentine (REMox-TB and Rifaquin trials). (b) Estimated and observed
results of the REMox-TB and Rifaquin trials, as indicated by the number of relapse-free (CFU-free) patients (per protocol analysis). (c)
Simulations of patient outcomes in TBTC study 31. (d) Simulations of patient outcomes in a hypothetical trial of a 4-month high-dose
rifampin-containing regimen. E, ethambutol; H, isoniazid; M, moxifloxacin; P, rifapentine; R, rifampin; Z, pyrazinamide. PK parameters
observed in clinical trials and PD parameters obtained from the mouse studies were used for the simulations (Table 2). Solid lines are
the mean predicted CFU counts (black) and plasma concentrations (rifampin, blue; moxifloxacin, green; rifapentine, red). Gray-shaded
areas are the areas between the lower and upper limits of the 95% confidence intervals of the predicted CFU counts. Dosing schedule:
REMox-TB trial, control arm: (months 0–2) rifampin 10 mg/kg, isoniazid 300 mg, pyrazinamide 25 mg/kg, and ethambutol 20 mg/kg, daily;
(months 2–6) rifampin 10 mg/kg and isoniazid 300 mg daily. Ethambutol arm: (months 0–2) rifampin 10 mg/kg, moxifloxacin 400 mg,
pyrazinamide 25mg/kg, and ethambutol 20 mg/kg daily; (months 2–4) rifampin 10 mg/kg and moxifloxacin 400 mg daily. Rifaquin trial,
control arm: (months 0–2) rifampin 10 mg/kg, isoniazid 300 mg, pyrazinamide 25 mg/kg, and ethambutol 20 mg/kg daily; (months 2–6)
rifampin 10 mg/kg and isoniazid 300 mg daily. Four-month arm: (months 0–2) rifampin 10 mg/kg, moxifloxacin 400 mg, pyrazinamide
25 mg/kg, and ethambutol 20 mg/kg daily; (months 2–4) rifapentine 15 mg/kg and moxifloxacin 400 mg twice weekly. Six-month arm:
(months 0–2) rifampin 10 mg/kg, moxifloxacin 400 mg, pyrazinamide 25 mg/kg, and ethambutol 20 mg/kg daily; (months 2–6) rifapentine
20 mg/kg and moxifloxacin 400 mg weekly. TBTC study 31, control arm: (months 0–2) rifampin 10 mg/kg, isoniazid 300 mg, pyrazinamide
25 mg/kg, and ethambutol 20 mg/kg daily; (months 2–6) rifampin 10 mg/kg and isoniazid 300 mg daily. Four-month arm: rifapentine arm:
(months 0–2) rifapentine 1200 mg, isoniazid 300 mg, pyrazinamide 25 mg/kg and ethambutol 20 mg/kg daily; (months 2–4) rifapentine
1,200mg and isoniazid 300mg daily. Rifapentine andmoxifloxacin arm: (months 0–2) rifapentine 1,200mg, isoniazid 300mg, moxifloxacin
400 mg, and pyrazinamide 25 mg/kg daily; (months 2–4) rifapentine 1,200 mg, isoniazid 300 mg, and moxifloxacin 400 mg daily.
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The high success rates predicted with either high-dose
rifamycin regimens suggest that the translational model
can inform regimen optimization and predict outcomes of
late-stage clinical trials. The results of these ongoing trials
will determine the accuracy of these predictions.
DISCUSSION
Mouse models have been used for decades to evaluate new
TB drugs and regimens and to inform clinical trials. Selection
of regimens to test in phase II/III trials to shorten treatment
duration relies heavily on results in mice. However, disap-
pointing results of recent trials of fluoroquinolone-containing
regimens and the imperfect translation of rifapentine dose-
responses observed in BALB/c mice,3,7,11,12,19 suggest that
knowledge gained from preclinical investigations was not uti-
lized fully in informing dose selection and regimen optimiza-
tion. Therefore, we developed a translational PK/PD model
describing M. tuberculosis growth in mice, effects of the
adaptive immune response on bacterial growth, and relation-
ships between drug concentration and accelerated bacte-
rial death in mice. We expanded the model to include clin-
ical steady-state PK data, species-specific protein binding,
drug-drug interactions, and patient-specific pathology (e.g.,
cavitary disease). This translational PK/PDmodel adequately
predicted exposure-response relationships of rifamycins and
long-term outcomes observed in recent clinical trials. In
addition, the validated model predicted minimal risk of
relapse at 1 year following 4 months of treatment with high-
dose rifapentine regimens in the ongoing TBTC study 31
(NCT02410772) and with high-dose rifampin regimens in the
ongoing RIFASHORT trial (NCT02581527). This provides a
basis for prospective evaluations to determine the predictive
accuracy of the model.
The challenges of interpreting preclinical PK/PD data for
TB drugs require advanced PK/PD modeling techniques.
Treatment outcomes in mice were highly influenced by
experimental variables, such as the infectious dose, incu-
bation period, and immune status. Moreover, there is great
interindividual variability in lung pathology in patients with
TB, in which the extent of caseous disease, presence or
absence of cavitation, and size of cavities influence drug dis-
tribution and treatment outcomes. In contrast, the mouse
strains used in the experiments that informed the model
do not develop caseous lung lesions. Accounting for the
influence of such lesions improved the translational model.
Recent advances in developing more pathologically repre-
sentative animal models41,42 and new approaches for study-
ing drug concentrations at the site of infection43 have laid the
groundwork for further study of the impact of tissue pathol-
ogy on regimen efficacy. Further research should focus on
lesion heterogeneity and its impacts on drug distribution and
efficacy, the metabolic state of bacteria and microenviron-
mental conditions affecting drug action.
We quantified the adaptive immune effect for the pur-
pose of quantifying the true drug effect (contribution of drug
alone to efficacy), which can now be applied to estimate
drug efficacy in immunodeficient patients. Simulations with
the final translational model show a greater contribution of
the immune system to bacterial killing and treatment out-
come in patients receiving standard-dose rifampin compared
with high-dose rifapentine. This suggests that in patients
with advanced human immunodeficiency virus infection,
rifapentinemay be preferred over rifampin, as suggested by a
study in athymic nude mice.44 This effect is likely due to mas-
sive killing of intracellular bacilli by high-dose rifapentine, but
the precise mechanisms of such immune-mediated effects
require further study.
Combining isoniazid and pyrazinamide with rifampin or
rifapentine had only a limited beneficial or even a slight antag-
onistic effect on bacterial clearance in this model, consis-
tent with previous studies demonstrating potential antago-
nistic effects in mice and human patients.45,46 However, the
ability to discriminate the effects of individual agents used
in combinations was limited by the available data. We are
currently working to incorporate more variations in compo-
nent drug combinations (including monotherapy) and drug
doses. This will enhance our understanding of the pharmaco-
dynamic interactions and the contribution to the sum effect
of these drugs in combination, which will be useful to study
new drug combinations.
Our translational modeling approach can be extended to
the prediction of clinical trial outcomes for regimens com-
prised of other TB drugs and for other diseases in which
a largely invariant relationship exists between drug expo-
sure and effect at the site of action in preclinical models
and in patients, such as other infections, cancer, pain, and
neurological diseases. An example of a similar approach
in cancer is provided by Betts et al.47 who developed a
translational PK/PD model of inotuzumab ozogamicin for
acute lymphocytic leukemia using preclinical and clinical
data.
In conclusion, we built a translational PK/PD model to pre-
dict clinical outcomes utilizing preclinical exposure-response
data, information about disease pathology, and immune
responses linked with clinical PK and validated the model
based on long-term outcomes of recent clinical trials. This
model can inform design and predict outcomes of phase II/III
trials of new TB regimens, such as TBTC study 31 and the
RIFASHORT trial. When enhanced with individual effects of
each drug and additional cross-species PK/PD response dif-
ferences related to differences in pathology in future studies,
this model is expected to provide better predictions of trial
outcomes for new regimens in development. Our approach
is relevant for researchers working across disease areas to
bridge the preclinical-clinical divide in more efficient and
informative ways.
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